Three recent landmark trials have redefined the standard of care for patients with nonmetastatic, castrate-resistant prostate cancer (nmCRPC).1-4 These trials demonstrate that for men with nmCRPC and a prostate-specific antigen doubling time of 10 months or fewer, the addition of a second-generation androgen signaling inhibitor (ASI) to androgen deprivation therapy (ADT) prolongs not only metastasis-free survival (MFS) but also overall survival.